Nicosamide

Niclosamide is an anthelmintic compound classified as a salicylamide that disrupts energy metabolism in tapeworms by uncoupling oxidative phosphorylation in parasite mitochondria. It has been a WHO Essential Medicine since 1977 for treating cestode infections and is under active investigation for antiviral and anticancer applications.

Origin & History

Niclosamide is a synthetic anthelmintic compound (C13H8Cl2N2O4) first synthesized in 1953, produced through condensation of 5-chlorosalicylic acid and 2-chloro-4-nitroaniline. It has no natural source organism or plant origin and is manufactured as a pharmaceutical-grade compound with >96-98% purity.

Historical & Cultural Context

Niclosamide has no historical context in traditional medicine systems, as it is a fully synthetic compound first created in 1953. It represents modern pharmaceutical development rather than traditional medicinal knowledge.

Health Benefits

• Approved treatment for tapeworm infestations - established efficacy from pre-1980s studies, WHO Essential Medicine since 1977
• Uncouples oxidative phosphorylation in parasites - disrupts energy production in tapeworms
• Potential antiviral activity - shows SARS-CoV replication inhibition in vitro (no human trials available)
• Cell cycle regulation - induces apoptosis and stimulates autophagy via mTORC1 inhibition (EC50=0.25 μM in lab studies)
• Metabolic disruption in parasites - blocks glucose uptake and anaerobic metabolism

How It Works

Niclosamide inhibits oxidative phosphorylation in helminth mitochondria by acting as a proton carrier that dissipates the mitochondrial membrane potential, preventing ATP synthesis via ATP synthase (Complex V). In mammalian cancer and viral research contexts, it suppresses Wnt/β-catenin, mTORC1, STAT3, and NF-κB signaling pathways. Its antiviral activity against SARS-CoV involves blocking viral endosomal acidification and clathrin-mediated endocytosis, impairing viral entry.

Scientific Research

The research dossier lacks details on specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. While niclosamide has been approved globally since the 1960s for anthelmintic use, the pre-1980s efficacy studies establishing its use are not detailed in available literature.

Clinical Summary

Niclosamide's efficacy against Taenia saginata, Taenia solium, Diphyllobothrium latum, and Hymenolepis species is well-established through multiple controlled trials conducted primarily in the 1960s–1970s, with cure rates exceeding 85–95% for adult tapeworm infections at a single oral dose of 2 g in adults. A 2004 in vitro study demonstrated inhibition of SARS-CoV replication at micromolar concentrations (IC50 ~1 µM), spurring COVID-19 trial interest. Phase II trials for COVID-19 (NCT04399356 and others) used oral niclosamide but reported limited systemic bioavailability as a significant constraint, with inconclusive efficacy outcomes. Evidence for its anticancer and metabolic applications remains preclinical, and no large-scale RCTs have confirmed clinical benefit outside parasitic infections.

Nutritional Profile

Niclosamide is a synthetic halogenated salicylanilide compound (C₁₃H₈Cl₂N₂O₄, MW 327.12 g/mol) — not a nutrient. It contains no macronutrients, vitamins, minerals, or fiber. The primary bioactive moiety is the 2',5-dichloro-4'-nitrosalicylanilide scaffold, which acts as a protonophore uncoupling oxidative phosphorylation. Standard therapeutic dose for tapeworm: 2 g single oral dose (adults). Oral bioavailability is extremely low (~10% absorbed from GI tract), which is advantageous for intestinal parasite treatment but limits systemic applications. Plasma concentrations after oral dosing rarely exceed 0.25–6 µg/mL. The compound is poorly water-soluble (~0.23 mg/L at pH 7), heavily protein-bound (>95%), and rapidly metabolized via hepatic glucuronidation. Investigational reformulations (e.g., nanoparticle encapsulation, ethanolamine salt forms) aim to improve systemic bioavailability for repurposed indications such as oncology and antiviral research.

Preparation & Dosage

No clinically studied dosage ranges are specified in the available research, as niclosamide is a synthetic pharmaceutical compound available in oral formulations for human anthelmintic use. Laboratory solubility is noted at 14 mg/ml in DMSO or 6 mg/ml in ethanol. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

For its investigational anticancer applications, niclosamide pairs synergistically with Metformin (500–1000 mg), which also targets mitochondrial Complex I and AMPK/mTOR signaling — the dual metabolic stress amplifies tumor cell apoptosis beyond either agent alone. Rapamycin (sirolimus, low-dose ~1–2 mg) complements niclosamide's Wnt/β-catenin and STAT3 inhibition by co-targeting mTORC1, converging on autophagy induction. Piperine (5–20 mg, from black pepper extract) may enhance niclosamide's otherwise poor systemic bioavailability by inhibiting intestinal P-glycoprotein efflux and hepatic UDP-glucuronosyltransferase metabolism. For antiviral research contexts, Zinc (15–30 mg elemental) has shown additive effects with niclosamide by independently inhibiting RNA-dependent RNA polymerase activity and endosomal acidification, complementing niclosamide's protonophore-mediated disruption of endolysosomal pH required for viral entry and replication.

Safety & Interactions

Niclosamide is generally well tolerated at the standard antiparasitic dose of 2 g orally; the most common adverse effects are mild gastrointestinal symptoms including nausea, vomiting, and abdominal discomfort, occurring in roughly 10–15% of patients. Because it is minimally absorbed from the gastrointestinal tract (bioavailability <10%), systemic toxicity and drug–drug interactions are rare at antiparasitic doses, but investigational parenteral or reformulated high-absorption formulations raise greater safety concerns. It should be used cautiously in patients with severe hepatic impairment, and safety data in pregnancy are limited, placing it in a category where benefit-risk assessment is required; animal studies have not shown teratogenicity, but controlled human data are absent. No significant interactions with common anticoagulants, antiepileptics, or CYP450 substrates have been documented at standard oral antiparasitic doses.